AdenovirusNCT03325517
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
An observational study of Adenovirus, run by Heba Momen kamel.
Trial summary
BACKGROUND: The 243 amino acid E1A encoded by the left end of the human adenovirus (Ad) type 2 or 5 genome has been studied in various contexts including as a model cooperating oncoprotein , an apoptosis inducing protein, and as a therapeutic oncolytic protein. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Adenovirus
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2017to 1 Sep 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients who are positive for adenovirus (symptomatic or not)
Who may be able to join
- All patients who are positive for adenovirus
Who cannot join
- immune comprised patients
About this study
BACKGROUND:
The 243 amino acid E1A encoded by the left end of the human adenovirus (Ad) type 2 or 5 genome has been studied in various contexts including as a model cooperating oncoprotein , an apoptosis inducing protein, and as a therapeutic oncolytic protein. All of these properties are associated with its capacity to rapidly induce S phase in a variety of cells. E1A orchestrates most of these effects by interacting with an array of chromatin remodeling complexes, including the Rb family proteins, and the HAT proteins p300 and CBP.
Read more
The Myst family protein HBO1 (Myst2, KAT7) is a histone acetyl transferase that plays a major role in replication initiation and also contributes to DNA re-replication. HBO1 directly interacts with Cdt1 and functions as a coactivator of Cdt1 in replication initiation. It also associates with replication origin and stimulates origin activation by acetylating H4 K5, K8, and K12. Overexpression of HBO1 induces DNA re-replication.
SPECIFIC AIM OF THE STUDY: The Specific Aim of this study is to determine whether or not the stimulation of HBO1 activity by E1A plays a role in deregulated DNA replication, and if it does, to determine the mechanism.
- Using standard assays the investigators will determine whether E1A binds to HBO1 to induce its HAT activity
- The investigators will determine whether E1A stimulation of HAT activity of HBO1 contributes to DNA re-replication.
RESEARCH DESIGN AND METHODS:
First, the investigators will determine whether E1A associates with replication origins and whether this association requires HBO1. The investigators will use the MCM4 origin which maps in the intergenic region between PRKDC and (Protein Kinase, DNA-Activated, Catalytic Polypeptide) and MCM4 genes.
The investigators will transfect U2OS cells with plasmids expressing relevant proteins then determine their occupancy in origin sequences using ChIP assays. Plasmids expressing epitope tagged WT HBO1 or mutant derivatives along with plasmids expressing WT or mutant E1A proteins will be expressed in U2OS cells, then occupancy of these proteins on origin regions will be quantified using antibodies as appropriate. Typically in these experiments, using relevant antibodies, ChIP assays are performed with primer pairs encompassing origin regions and also regions that are far from origin. Occupancy of initiation factors are increased several fold in the origin region as compared to that of 2KB upstream or downstream regions. Loading of MCM complex along with Cdt1 onto the origins is an indication that initiation of replication occurs in that origin and usually assayed in ChIP-re-ChIP assays as follows: First, loading of HBO1 to the origins will be confirmed using epitope specific antibodies in the first ChIP. The anti-HBO1 precipitates will be re-ChIPed with anti-MCM3 antibodies. Loading of MCM3 helicase to origins occurs after Cdt1 binding and depends on HBO1 HAT activity. Normal amounts of MCM3 will be detected after re-ChIP-ing in E1A+ control samples. If reduced amount of MCM3 is recovered in reChIP assays when mutant E1A or HBO1 mutant (e.g. HBO1 G435A) is used, it would indicate that stimulation of HAT activity by E1A is critical for maximal origin activity in E1A+ cells. This type of assay has considerable flexibility in that mutant proteins can be rapidly assayed. This ChIP-reChiP assays will repeated in different combinations to determine the E1A loading.
These results will be extended to virus infection assays. G1 specific cells isolated by drug treatment will be infected with Ad vectors expressing epitope tagged proteins as appropriate. Association of E1A and HBO1 and their mutant derivatives will be determined. This assay will allow us to confirm the effect of E1A stimulated HAT activity in origin firing and study the effects of E1A on origin firing, if any, other than increasing the HAT activity of HBO1.
Read the detailed description
BACKGROUND:
TThe 243 amino acid E1A protein (also known as small E1A protein, transforming E1A protein) encoded by the left end of the human adenovirus (Ad) type 2 or 5 genome has been studied in various contexts including as a model cooperating oncoprotein, an apoptosis inducing protein, and as a therapeutic oncolytic protein. All of these properties are associated with its capacity to rapidly induce S phase in a variety of cells. E1A orchestrates most of these effects by interacting with an array of chromatin remodeling complexes, including the Rb family proteins, and the HAT proteins p300 and CBP.
The induction of E2F by E1A-Rb-HDAC interactions is well documented whereas the consequences of E1A-p300/CBP interactions in cell cycle progression are not clear. Previous studies demonstrated that p300/CBP prevents premature entry of quiescent cells into S phase by repressing c-Myc transcription through a tripartite repressor complex consisting of p300, YY1, HDAC3. E1A binds to p300 and dissociates the repressor complex to induce S phase. Induction of c-Myc by this mechanism contributes to the induction of DNA damage response and aberrant cellular DNA replication which leads to genomic instability. In a recently published study, it was shown that E1A induces the pivotal DNA replication initiation factor Cdt1 to high levels resulting in increased replication origin activity and in late S phase, induction of DNA damage response and cellular DNA re-replication. Using the single molecule DNA fiber assay, it was discovered that E1A induces significant changes in the dynamics of DNA replication and appears to induce global changes in origin activation.
Cdt1 is a pivotal DNA replication initiation factor whose levels oscillate during cell cycle progression. In late G1, its levels rise to initiate DNA replication. At the beginning of S phase it is promptly degraded by the E3 ligase so that origins that are already fired once do not fire again in S phase and re-replication within a single cell cycle does not occur. Impaired degradation of Cdt1 in S phase by the E3 ligase is the major mechanism by which the cellular DNA undergoes re-replication. It was discovered that in E1A expressing cells Cdt1 levels remain high in S phase suggesting an inefficient degradation of Cdt1 which may contribute to extensive re-replication of cellular DNA that the investigators observed in late S phase.
The Myst family protein HBO1 (Myst2, KAT7) is a histone acetyl transferase that plays a major role in replication initiation and also contributes to DNA re-replication. HBO1 directly interacts with Cdt1 and functions as a coactivator of Cdt1 in replication initiation. It also associates with replication origin and stimulates origin activation by acetylating H4 K5, K8, and K12. Overexpression of HBO1 induces DNA re-replication. The enrichment of chromatin modifications including acetylation of H4 histones at the origins strongly influences origin activation. Thus, E1A in the absence of a multitude of serum stimulated proliferation signals, forces cells to enter S phase using several compensatory mechanisms. Uncontrolled cellular DNA replication program causes polyploidy that is the hallmark of cancer. It is exciting that a viral oncogene such as E1A alters the cellular DNA replication program. This raises a number of important questions related to the mechanism of replication stress induced by a viral oncogene. For example, how does E1A induce DNA re-replication? Does E1A stimulation of HBO1 alter initiation mechanism and whether HBO1 mediated chromatin modifications at the origins promote re-replication?
SPECIFIC AIM OF THE STUDY:
Our Specific Aim is to determine whether or not the stimulation of HBO1 activity by E1A plays a role in deregulated DNA replication, and if it does, to determine the mechanism.
- Using standard assays the investigators will determine whether E1A binds to HBO1 to induce its HAT activity
- Using transient and virus infection assays, the investigators will determine whether stimulation of HBO1 HAT activity by E1A enhances the pre-replicative complex (Pre-RC) formation and whether E1A induced HAT activity qualitatively and quantitatively changes the H4 acetylation at the origin regions.
- the investigators will determine whether E1A stimulation of HAT activity of HBO1 contributes to DNA re-replication.
RESEARCH DESIGN AND METHODS:
The goal of this study is to determine whether stimulation of HBO1 HAT activity by E1A (i) enhances initiation (ii) induces qualitative and quantitative changes in acetylation of H4 K5, K8 and K12 at the origin region, and (iii) enhances re-replication that occurs in E1A+ cells. If increased HAT activity can stimulate one or more of these functions, it could explain how this property of E1A would contribute to the induction of aberrant DNA replication.
- E1A binding to WT and HAT deficient HBO1. the investigators will first determine whether E1A directly binds to HBO1 by performing the GST binding and in vivo co-IP experiments. If binding is confirmed, the investigators will map the binding sites on both proteins. the investigators will then isolate mutants of both proteins that abolish the interactions. All E1A mutants will be evaluated for their interactions with Rb and p300 and only mutants that retain their capacity to bind to these proteins will be used. It will be necessary to isolate an HBO1 mutant that retains E1A binding capacity but lacks the HAT activity. A widely used HAT deficient mutant G435A will be used in these studies. If E1A binds to this mutant, it will be a valuable mutant to confirm that E1A induced HAT activity is critical for stimulation of replication initiation. If this HBO1 mutant does not bind to E1A, it will be important to isolate new HBO1 mutants which retain E1A binding capacity but lack HAT activity.
- Role of E1A induced HBO1 HAT activity in origin activation: First, the investigators will determine whether E1A associates with replication origins and whether this association requires HBO1. the investigators will use the MCM4 origin which maps in the intergenic region between PRKDC and (Protein Kinase, DNA-Activated, Catalytic Polypeptide) and MCM4 genes. First, the investigators will transfect U2OS cells with plasmids expressing relevant proteins then determine their occupancy in origin sequences using ChIP assays. Plasmids expressing epitope tagged WT HBO1 or mutant derivatives along with plasmids expressing WT or mutant E1A proteins will be expressed in U2OS cells, then occupancy of these proteins on origin regions will be quantified using antibodies as appropriate. Typically in these experiments, using relevant antibodies, ChIP assays are performed with primer pairs encompassing origin regions and also regions that are far from origin. Occupancy of initiation factors are increased several fold in the origin region as compared to that of 2KB upstream or downstream regions. Loading of MCM complex along with Cdt1 onto the origins is an indication that initiation of replication occurs in that origin and usually assayed in ChIP-re-ChIP assays as follows: First, loading of HBO1 to the origins will be confirmed using epitope specific antibodies in the first ChIP. The anti-HBO1 precipitates will be re-ChIPed with anti-MCM3 antibodies. Loading of MCM3 helicase to origins occurs after Cdt1 binding and depends on HBO1 HAT activity. Normal amounts of MCM3 will be detected after re-ChIP-ing in E1A+ control samples. If reduced amount of MCM3 is recovered in reChIP assays when mutant E1A or HBO1 mutant (e.g. HBO1 G435A) is used, it would indicate that stimulation of HAT activity by E1A is critical for maximal origin activity in E1A+ cells. This type of assay which has been successfully used by others has considerable flexibility in that mutant proteins can be rapidly assayed. This ChIP-reChiP assays will repeated in different combinations to determine the E1A loading. These results will be extended to virus infection assays. G1 specific cells isolated by drug treatment will be infected with Ad vectors expressing epitope tagged proteins as appropriate. Association of E1A and HBO1 and their mutant derivatives will be determined. This assay will allow us to confirm the effect of E1A stimulated HAT activity in origin firing and study the effects of E1A on origin firing, if any, other than increasing the HAT activity of HBO1. For example, c-Myc induction by E1A does not involve HAT activity.
- Effects of E1A induced HBO1 HAT activity in the acetylation of H4, K5, K8 and K12. To assess this, the investigators will ChIP the chromatin prepared from virus infected cells with the origin specific primers and epitope specific antibodies as appropriate to detect origin loading of HBO1. the investigators will then re-Chip the ChIP precipitates using anti-H4 tetra-Ac antibodies to detect K5, K8, and K12 acetylation. In cells expressing E1A and HBO1, H4 acetylation will be increased considerably as compared to cells infected with HBO1 virus alone. H4 acetylation may be affected depending on the mutants used.
- E1A stimulated HBO1 HAT activity in re-replication. Overexpression of HBO1 has been shown to induce DNA-replication. To determine whether E1A uses HBO1 in inducing re-replication by stimulating the HBO1 HAT activity, the investigators will infect S phase enriched cells (isolated by double thymidine block) with Ad viruses expressing the WT or mutant E1A proteins along with Ad vectors expressing HBO1 variants (e.g. HAT inactive), allow the infection to proceed as needed then quantify the population of cells containing >4N DNA content using flow cytometer. If E1A simulated HBO1 HAT activity is important for re-replication HAT defective HBO1 mutants will not induce re-replication even in the presence of E1A. E1A mutants that cannot bind to HBO1 will also show a similar phenotype.
- E1A effects on H4 acetylations in re-replicating origins: In order to study the H4 acetylations in re-replicating origins, the investigators need to know which of cellular origins undergo re-replication in E1A+ cells in late S phase. the investigators are planning to identify the origins activated in E1A+ cells including those that re-replicate. Once the investigators identify one or two re-replicating origins, the investigators will quantify the acetylations using these origins in cells expressing epitope tagged WT and mutant HBO1 alleles and E1A. the investigators anticipate qualitative or quantitative (or both) in H4 acetylations due to E1A.
- Expected results and pitfalls:
At the end of all the proposed experiments, the investigators expect to determine whether stimulation of HBO1 HAT activity by E1A is critical for origin activation in E1A+ cells and if E1A induced HAT activity has a role in re-replication. The investigators do not anticipate any technical or other problems including obtaining relevant reagents.
- Conditions
- Adenovirus
- Medical subject headings
- Adenoviridae Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
DNA re-replication indicated by the number of cells containing >4N DNA content using flow cytometer
To determine whether E1A uses HBO1 in inducing re-replication by stimulating the HBO1 HAT activity, the investigators will infect S phase enriched cells (isolated by double thymidine block) with Ad viruses expressing the WT or mutant E1A proteins along with Ad vectors expressing HBO1 variants (e.g. HAT inactive), allow the infection to proceed as needed then quantify the population of cells containing >4N DNA content using flow cytometer. If E1A simulated HBO1 HAT activity is important for re-replication HAT defective HBO1 mutants will not induce re-replication even in the presence of E1A. E1A mutants that cannot bind to HBO1 will also show a similar phenotype.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2017
- Study start1 Nov 2017 (estimated)
- Primary completion1 Sep 2018 (estimated)
- Study completion1 Sep 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (28)Papers the sponsor has linked to this study.
- Other trials for AdenovirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heba Momen kamel
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Heba Momen kamel, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03325517
- Sponsor's protocol ID
- 17200086.
- Status last verified
- Oct 2017
- First submitted
- 24 Oct 2017
- Last updated
- 30 Oct 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology. 2009 Feb 20;384(2):285-93. doi: 10.1016/j.virol.2008.09.034. Epub 2008 Dec 11.
PubMed 19081592Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene. 2005 Nov 21;24(52):7673-85. doi: 10.1038/sj.onc.1209040.
PubMed 16299528DeCaprio JA. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology. 2009 Feb 20;384(2):274-84. doi: 10.1016/j.virol.2008.12.010. Epub 2009 Jan 17.
PubMed 19150725Breckenridge DG, Shore GC. Regulation of apoptosis by E1A and Myc oncoproteins. Crit Rev Eukaryot Gene Expr. 2000;10(3-4):273-80. doi: 10.1615/critreveukargeneexpr.v10.i3-4.50.
PubMed 11272469Lavia P, Mileo AM, Giordano A, Paggi MG. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene. 2003 Sep 29;22(42):6508-16. doi: 10.1038/sj.onc.1206861.
PubMed 14528275Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Adv Exp Med Biol. 2007;608:144-69. doi: 10.1007/978-0-387-74039-3_11.
PubMed 17993239Deissler H, Opalka B. Therapeutic transfer of DNA encoding adenoviral E1A. Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):1-10. doi: 10.2174/157489207779561471.
PubMed 18221050Smith JG, Wiethoff CM, Stewart PL, Nemerow GR. Adenovirus. Curr Top Microbiol Immunol. 2010;343:195-224. doi: 10.1007/82_2010_16.
PubMed 20376613Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev. 1993 Feb;3(1):63-70. doi: 10.1016/s0959-437x(05)80342-9.
PubMed 8453277Kolli S, Buchmann AM, Williams J, Weitzman S, Thimmapaya B. Antisense-mediated depletion of p300 in human cells leads to premature G1 exit and up-regulation of c-MYC. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4646-51. doi: 10.1073/pnas.081141998.
PubMed 11296295Baluchamy S, Rajabi HN, Thimmapaya R, Navaraj A, Thimmapaya B. Repression of c-Myc and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9524-9. doi: 10.1073/pnas.1633700100. Epub 2003 Jul 25.
PubMed 12883011Rajabi HN, Baluchamy S, Kolli S, Nag A, Srinivas R, Raychaudhuri P, Thimmapaya B. Effects of depletion of CREB-binding protein on c-Myc regulation and cell cycle G1-S transition. J Biol Chem. 2005 Jan 7;280(1):361-74. doi: 10.1074/jbc.M408633200. Epub 2004 Nov 2.
PubMed 15522869Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S, Thimmapaya B. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene. 2008 Sep 25;27(43):5717-28. doi: 10.1038/onc.2008.181. Epub 2008 Jun 9.
PubMed 18542060Kadeppagari RK, Sankar N, Thimmapaya B. Adenovirus transforming protein E1A induces c-Myc in quiescent cells by a novel mechanism. J Virol. 2009 May;83(10):4810-22. doi: 10.1128/JVI.02145-08. Epub 2009 Mar 11.
PubMed 19279113Sankar N, Kadeppagari RK, Thimmapaya B. c-Myc-induced aberrant DNA synthesis and activation of DNA damage response in p300 knockdown cells. J Biol Chem. 2009 May 29;284(22):15193-205. doi: 10.1074/jbc.M900776200. Epub 2009 Mar 30.
PubMed 19332536
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
- ClinicalTrials.gov ID
- NCT03325517
- Acronym / sponsor ID
- 17200086.
- Conditions
- Adenovirus
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Heba Momen kamelUniversity, hospital or other
- Study start
- 1 Nov 2017 (estimated)
- Primary completion
- 1 Sep 2018 (estimated)
- Study completion
- 1 Sep 2019 (estimated)
- First posted
- 30 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND:
The 243 amino acid E1A encoded by the left end of the human adenovirus (Ad) type 2 or 5 genome has been studied in various contexts including as a model cooperating oncoprotein , an apoptosis inducing protein, and as a therapeutic oncolytic protein. All of these properties are associated with its capacity to rapidly induce S phase in a variety of cells. E1A orchestrates most of these effects by interacting with an array of chromatin remodeling complexes, including the Rb family proteins, and the HAT proteins p300 and CBP.
The Myst family protein HBO1 (Myst2, KAT7) is a histone acetyl transferase that plays a major role in replication initiation and also contributes to DNA re-replication. HBO1 directly interacts with Cdt1 and functions as a coactivator of Cdt1 in replication initiation. It also associates with replication origin and stimulates origin activation by acetylating H4 K5, K8, and K12. Overexpression of HBO1 induces DNA re-replication.
SPECIFIC AIM OF THE STUDY: The Specific Aim of this study is to determine whether or not the stimulation of HBO1 activity by E1A plays a role in deregulated DNA replication, and if it does, to determine the mechanism.
- Using standard assays the investigators will determine whether E1A binds to HBO1 to induce its HAT activity
- The investigators will determine whether E1A stimulation of HAT activity of HBO1 contributes to DNA re-replication.
RESEARCH DESIGN AND METHODS:
First, the investigators will determine whether E1A associates with replication origins and whether this association requires HBO1. The investigators will use the MCM4 origin which maps in the intergenic region between PRKDC and (Protein Kinase, DNA-Activated, Catalytic Polypeptide) and MCM4 genes.
The investigators will transfect U2OS cells with plasmids expressing relevant proteins then determine their occupancy in origin sequences using ChIP assays. Plasmids expressing epitope tagged WT HBO1 or mutant derivatives along with plasmids expressing WT or mutant E1A proteins will be expressed in U2OS cells, then occupancy of these proteins on origin regions will be quantified using antibodies as appropriate. Typically in these experiments, using relevant antibodies, ChIP assays are performed with primer pairs encompassing origin regions and also regions that are far from origin. Occupancy of initiation factors are increased several fold in the origin region as compared to that of 2KB upstream or downstream regions. Loading of MCM complex along with Cdt1 onto the origins is an indication that initiation of replication occurs in that origin and usually assayed in ChIP-re-ChIP assays as follows: First, loading of HBO1 to the origins will be confirmed using epitope specific antibodies in the first ChIP. The anti-HBO1 precipitates will be re-ChIPed with anti-MCM3 antibodies. Loading of MCM3 helicase to origins occurs after Cdt1 binding and depends on HBO1 HAT activity. Normal amounts of MCM3 will be detected after re-ChIP-ing in E1A+ control samples. If reduced amount of MCM3 is recovered in reChIP assays when mutant E1A or HBO1 mutant (e.g. HBO1 G435A) is used, it would indicate that stimulation of HAT activity by E1A is critical for maximal origin activity in E1A+ cells. This type of assay has considerable flexibility in that mutant proteins can be rapidly assayed. This ChIP-reChiP assays will repeated in different combinations to determine the E1A loading.
These results will be extended to virus infection assays. G1 specific cells isolated by drug treatment will be infected with Ad vectors expressing epitope tagged proteins as appropriate. Association of E1A and HBO1 and their mutant derivatives will be determined. This assay will allow us to confirm the effect of E1A stimulated HAT activity in origin firing and study the effects of E1A on origin firing, if any, other than increasing the HAT activity of HBO1.
Detailed description
BACKGROUND:
TThe 243 amino acid E1A protein (also known as small E1A protein, transforming E1A protein) encoded by the left end of the human adenovirus (Ad) type 2 or 5 genome has been studied in various contexts including as a model cooperating oncoprotein, an apoptosis inducing protein, and as a therapeutic oncolytic protein. All of these properties are associated with its capacity to rapidly induce S phase in a variety of cells. E1A orchestrates most of these effects by interacting with an array of chromatin remodeling complexes, including the Rb family proteins, and the HAT proteins p300 and CBP.
The induction of E2F by E1A-Rb-HDAC interactions is well documented whereas the consequences of E1A-p300/CBP interactions in cell cycle progression are not clear. Previous studies demonstrated that p300/CBP prevents premature entry of quiescent cells into S phase by repressing c-Myc transcription through a tripartite repressor complex consisting of p300, YY1, HDAC3. E1A binds to p300 and dissociates the repressor complex to induce S phase. Induction of c-Myc by this mechanism contributes to the induction of DNA damage response and aberrant cellular DNA replication which leads to genomic instability. In a recently published study, it was shown that E1A induces the pivotal DNA replication initiation factor Cdt1 to high levels resulting in increased replication origin activity and in late S phase, induction of DNA damage response and cellular DNA re-replication. Using the single molecule DNA fiber assay, it was discovered that E1A induces significant changes in the dynamics of DNA replication and appears to induce global changes in origin activation.
Cdt1 is a pivotal DNA replication initiation factor whose levels oscillate during cell cycle progression. In late G1, its levels rise to initiate DNA replication. At the beginning of S phase it is promptly degraded by the E3 ligase so that origins that are already fired once do not fire again in S phase and re-replication within a single cell cycle does not occur. Impaired degradation of Cdt1 in S phase by the E3 ligase is the major mechanism by which the cellular DNA undergoes re-replication. It was discovered that in E1A expressing cells Cdt1 levels remain high in S phase suggesting an inefficient degradation of Cdt1 which may contribute to extensive re-replication of cellular DNA that the investigators observed in late S phase.
The Myst family protein HBO1 (Myst2, KAT7) is a histone acetyl transferase that plays a major role in replication initiation and also contributes to DNA re-replication. HBO1 directly interacts with Cdt1 and functions as a coactivator of Cdt1 in replication initiation. It also associates with replication origin and stimulates origin activation by acetylating H4 K5, K8, and K12. Overexpression of HBO1 induces DNA re-replication. The enrichment of chromatin modifications including acetylation of H4 histones at the origins strongly influences origin activation. Thus, E1A in the absence of a multitude of serum stimulated proliferation signals, forces cells to enter S phase using several compensatory mechanisms. Uncontrolled cellular DNA replication program causes polyploidy that is the hallmark of cancer. It is exciting that a viral oncogene such as E1A alters the cellular DNA replication program. This raises a number of important questions related to the mechanism of replication stress induced by a viral oncogene. For example, how does E1A induce DNA re-replication? Does E1A stimulation of HBO1 alter initiation mechanism and whether HBO1 mediated chromatin modifications at the origins promote re-replication?
SPECIFIC AIM OF THE STUDY:
Our Specific Aim is to determine whether or not the stimulation of HBO1 activity by E1A plays a role in deregulated DNA replication, and if it does, to determine the mechanism.
- Using standard assays the investigators will determine whether E1A binds to HBO1 to induce its HAT activity
- Using transient and virus infection assays, the investigators will determine whether stimulation of HBO1 HAT activity by E1A enhances the pre-replicative complex (Pre-RC) formation and whether E1A induced HAT activity qualitatively and quantitatively changes the H4 acetylation at the origin regions.
- the investigators will determine whether E1A stimulation of HAT activity of HBO1 contributes to DNA re-replication.
RESEARCH DESIGN AND METHODS:
The goal of this study is to determine whether stimulation of HBO1 HAT activity by E1A (i) enhances initiation (ii) induces qualitative and quantitative changes in acetylation of H4 K5, K8 and K12 at the origin region, and (iii) enhances re-replication that occurs in E1A+ cells. If increased HAT activity can stimulate one or more of these functions, it could explain how this property of E1A would contribute to the induction of aberrant DNA replication.
- E1A binding to WT and HAT deficient HBO1. the investigators will first determine whether E1A directly binds to HBO1 by performing the GST binding and in vivo co-IP experiments. If binding is confirmed, the investigators will map the binding sites on both proteins. the investigators will then isolate mutants of both proteins that abolish the interactions. All E1A mutants will be evaluated for their interactions with Rb and p300 and only mutants that retain their capacity to bind to these proteins will be used. It will be necessary to isolate an HBO1 mutant that retains E1A binding capacity but lacks the HAT activity. A widely used HAT deficient mutant G435A will be used in these studies. If E1A binds to this mutant, it will be a valuable mutant to confirm that E1A induced HAT activity is critical for stimulation of replication initiation. If this HBO1 mutant does not bind to E1A, it will be important to isolate new HBO1 mutants which retain E1A binding capacity but lack HAT activity.
- Role of E1A induced HBO1 HAT activity in origin activation: First, the investigators will determine whether E1A associates with replication origins and whether this association requires HBO1. the investigators will use the MCM4 origin which maps in the intergenic region between PRKDC and (Protein Kinase, DNA-Activated, Catalytic Polypeptide) and MCM4 genes. First, the investigators will transfect U2OS cells with plasmids expressing relevant proteins then determine their occupancy in origin sequences using ChIP assays. Plasmids expressing epitope tagged WT HBO1 or mutant derivatives along with plasmids expressing WT or mutant E1A proteins will be expressed in U2OS cells, then occupancy of these proteins on origin regions will be quantified using antibodies as appropriate. Typically in these experiments, using relevant antibodies, ChIP assays are performed with primer pairs encompassing origin regions and also regions that are far from origin. Occupancy of initiation factors are increased several fold in the origin region as compared to that of 2KB upstream or downstream regions. Loading of MCM complex along with Cdt1 onto the origins is an indication that initiation of replication occurs in that origin and usually assayed in ChIP-re-ChIP assays as follows: First, loading of HBO1 to the origins will be confirmed using epitope specific antibodies in the first ChIP. The anti-HBO1 precipitates will be re-ChIPed with anti-MCM3 antibodies. Loading of MCM3 helicase to origins occurs after Cdt1 binding and depends on HBO1 HAT activity. Normal amounts of MCM3 will be detected after re-ChIP-ing in E1A+ control samples. If reduced amount of MCM3 is recovered in reChIP assays when mutant E1A or HBO1 mutant (e.g. HBO1 G435A) is used, it would indicate that stimulation of HAT activity by E1A is critical for maximal origin activity in E1A+ cells. This type of assay which has been successfully used by others has considerable flexibility in that mutant proteins can be rapidly assayed. This ChIP-reChiP assays will repeated in different combinations to determine the E1A loading. These results will be extended to virus infection assays. G1 specific cells isolated by drug treatment will be infected with Ad vectors expressing epitope tagged proteins as appropriate. Association of E1A and HBO1 and their mutant derivatives will be determined. This assay will allow us to confirm the effect of E1A stimulated HAT activity in origin firing and study the effects of E1A on origin firing, if any, other than increasing the HAT activity of HBO1. For example, c-Myc induction by E1A does not involve HAT activity.
- Effects of E1A induced HBO1 HAT activity in the acetylation of H4, K5, K8 and K12. To assess this, the investigators will ChIP the chromatin prepared from virus infected cells with the origin specific primers and epitope specific antibodies as appropriate to detect origin loading of HBO1. the investigators will then re-Chip the ChIP precipitates using anti-H4 tetra-Ac antibodies to detect K5, K8, and K12 acetylation. In cells expressing E1A and HBO1, H4 acetylation will be increased considerably as compared to cells infected with HBO1 virus alone. H4 acetylation may be affected depending on the mutants used.
- E1A stimulated HBO1 HAT activity in re-replication. Overexpression of HBO1 has been shown to induce DNA-replication. To determine whether E1A uses HBO1 in inducing re-replication by stimulating the HBO1 HAT activity, the investigators will infect S phase enriched cells (isolated by double thymidine block) with Ad viruses expressing the WT or mutant E1A proteins along with Ad vectors expressing HBO1 variants (e.g. HAT inactive), allow the infection to proceed as needed then quantify the population of cells containing >4N DNA content using flow cytometer. If E1A simulated HBO1 HAT activity is important for re-replication HAT defective HBO1 mutants will not induce re-replication even in the presence of E1A. E1A mutants that cannot bind to HBO1 will also show a similar phenotype.
- E1A effects on H4 acetylations in re-replicating origins: In order to study the H4 acetylations in re-replicating origins, the investigators need to know which of cellular origins undergo re-replication in E1A+ cells in late S phase. the investigators are planning to identify the origins activated in E1A+ cells including those that re-replicate. Once the investigators identify one or two re-replicating origins, the investigators will quantify the acetylations using these origins in cells expressing epitope tagged WT and mutant HBO1 alleles and E1A. the investigators anticipate qualitative or quantitative (or both) in H4 acetylations due to E1A.
- Expected results and pitfalls:
At the end of all the proposed experiments, the investigators expect to determine whether stimulation of HBO1 HAT activity by E1A is critical for origin activation in E1A+ cells and if E1A induced HAT activity has a role in re-replication. The investigators do not anticipate any technical or other problems including obtaining relevant reagents.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients who are positive for adenovirus (symptomatic or not)
Key inclusion criteria (1 listed)
- All patients who are positive for adenovirus
Key exclusion criteria (1 listed)
- immune comprised patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
DNA re-replication indicated by the number of cells containing >4N DNA content using flow cytometer
Time frame: 1 year
To determine whether E1A uses HBO1 in inducing re-replication by stimulating the HBO1 HAT activity, the investigators will infect S phase enriched cells (isolated by double thymidine block) with Ad viruses expressing the WT or mutant E1A proteins along with Ad vectors expressing HBO1 variants (e.g. HAT inactive), allow the infection to proceed as needed then quantify the population of cells containing >4N DNA content using flow cytometer. If E1A simulated HBO1 HAT activity is important for re-replication HAT defective HBO1 mutants will not induce re-replication even in the presence of E1A. E1A mutants that cannot bind to HBO1 will also show a similar phenotype.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2017.
- Background: PubMed 19081592Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology. 2009 Feb 20;384(2):285-93. doi: 10.1016/j.virol.2008.09.034. Epub 2008 Dec 11.
- Background: PubMed 16299528Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene. 2005 Nov 21;24(52):7673-85. doi: 10.1038/sj.onc.1209040.
- Background: PubMed 19150725DeCaprio JA. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology. 2009 Feb 20;384(2):274-84. doi: 10.1016/j.virol.2008.12.010. Epub 2009 Jan 17.
- Background: PubMed 11272469Breckenridge DG, Shore GC. Regulation of apoptosis by E1A and Myc oncoproteins. Crit Rev Eukaryot Gene Expr. 2000;10(3-4):273-80. doi: 10.1615/critreveukargeneexpr.v10.i3-4.50.
- Background: PubMed 14528275Lavia P, Mileo AM, Giordano A, Paggi MG. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene. 2003 Sep 29;22(42):6508-16. doi: 10.1038/sj.onc.1206861.
- Background: PubMed 17993239Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Adv Exp Med Biol. 2007;608:144-69. doi: 10.1007/978-0-387-74039-3_11.
- Background: PubMed 18221050Deissler H, Opalka B. Therapeutic transfer of DNA encoding adenoviral E1A. Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):1-10. doi: 10.2174/157489207779561471.
- Background: PubMed 20376613Smith JG, Wiethoff CM, Stewart PL, Nemerow GR. Adenovirus. Curr Top Microbiol Immunol. 2010;343:195-224. doi: 10.1007/82_2010_16.
- Background: PubMed 8453277Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev. 1993 Feb;3(1):63-70. doi: 10.1016/s0959-437x(05)80342-9.
- Background: PubMed 11296295Kolli S, Buchmann AM, Williams J, Weitzman S, Thimmapaya B. Antisense-mediated depletion of p300 in human cells leads to premature G1 exit and up-regulation of c-MYC. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4646-51. doi: 10.1073/pnas.081141998.
- Background: PubMed 12883011Baluchamy S, Rajabi HN, Thimmapaya R, Navaraj A, Thimmapaya B. Repression of c-Myc and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9524-9. doi: 10.1073/pnas.1633700100. Epub 2003 Jul 25.
- Background: PubMed 15522869Rajabi HN, Baluchamy S, Kolli S, Nag A, Srinivas R, Raychaudhuri P, Thimmapaya B. Effects of depletion of CREB-binding protein on c-Myc regulation and cell cycle G1-S transition. J Biol Chem. 2005 Jan 7;280(1):361-74. doi: 10.1074/jbc.M408633200. Epub 2004 Nov 2.
- Individual participant dataSharing planned: Undecided
Related trials for Adenovirus
RecruitingPhase 2
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
Adenovirus, Primary Immune Deficiency Disorder
Not yet recruitingEarly Phase 1
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
EBV Viremia, CMV Viremia
RecruitingPhase 3
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
Adenovirus Infections
RecruitingEarly Phase 1
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus
RecruitingPhase 3
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
CMV, AdV Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Adenovirus, run by Heba Momen kamel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DNA re-replication indicated by the number of cells containing >4N DNA content using flow cytometer (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03325517, which also lists 28 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2017; AzTrials last refreshed its copy on 30 Oct 2026.